oracle puts it out there....., page-58

Hi born2reign,

I'm assuming that SK-II Phase II and SK-II Wave II may be referring to the same thing, yes. That is to suggest that SK-II and OBJ may be working on new product format based on existing actives/formulations that SK-II are marketing (i.e. The SK-II Stempower Eye Cream evolved from the SK-II Stempower Cream and was released to the market a few months before SK-II introduced the SK-II Magnetic Eye Wand). How much (if any) tweaking may be necessary with existing formulations for enhancing compatibility with OBJ's micro-arrays, I really don't know?

In regards to the discrepancies noted in work plans or new product developments under the initial PDA executed with P&G in April last year, I think this is a theme that we may come to expect in some regards as separate business units within P&G over time will be presenting OBJ with additional proposals to new product development solutions they are looking for.

To my understanding, when these are presented to OBJ there are a number of steps that OBJ's technical/scientific team must then undertake to be able to properly evaluate each opportunity, i.e. can OBJ's microarray technologies move the partners' selected molecule(s) more effectively than passive diffusion, if so, how much enhancement can be provided, and will this translate to consumer benefit. Answers to these questions require extensive internal study programs prior to prototype development by OBJ and finally P&G controlled clinical study programs for quantifying efficacy and validating new product claims.

P&G conduct over 20,000 clinical trials each year and to date we have only been advised of three clinical trials being controlled by P&G which commenced in 2013 to investigate OBJ's technologies - the first of which produced the best results that have ever been achieved in any clinical study conducted by P&G.

I've always been under the impression that P&G initially proposed 8 product development work plans covering 7 major product categories - 3 of which were executed and 4 which were under final planning as per announcement on 28/04/2014 - to the best of my knowledge the Company were not sure about approving work plan number 8 proposed by P&G and therefore probably chose to omit it from that initial release - whether that had anything to do with the compatibility or atomic structure to OBJ's technologies or whether completely unrelated, I really don't know. I do understand that Gillette may have approached OBJ in relation to the moisture strips on its razors but I'm not exactly sure what solution they were looking for, nor exactly how OBJ's technology platforms would accommodate those needs?

Over time I certainly anticipate that we will see this partnership extending the scope of the initial PDA agreement quite substantially. P&G's New Business Creation Group which was established in 2013 is working directly with OBJ, and reports directly to Mr A.G. Lafley. You can't get anymore intimate than that with the world's largest consumer goods company

I haven't, however Mr J Palermo Snr has passed away since that notice, and I believe most of the legal wrangling's between him and his brother were relating to the distribution of Mr Palermo's assets as he had been in bad health for some time. In regards to the con note I don't think there's much for us to be concerned about as it expired in 2012.